On January 4, the H. Lee Moffitt Cancer Center & Research Institute Hospital Inc. of Florida (Moffitt) agreed to pay US$19.5 million to resolve its civil liability under the False Claims Act (FCA) related to alleged conduct occurring from May 11, 2014 through May 10, 2020.
Donanemab, an Alzheimer's drug candidate produced by Eli Lilly, showed that it can slow cognitive decline by 35% in the company's new Phase 3 study, but there are some safety risks – exemplified by two deaths that occurred during the trial that were attributed to brain swelling, according to the drug company. In addition to the risk of brain swelling, the trial showed that
A new Optum report highlighting upcoming medications in the drug pipeline is meant as a heads-up for payers as they track developments with a couple of therapies for Alzheimer's disease – lecanemab and donanemab. Lecanemab, from Eisai/Biogen, is under review for the treatment of mild cognitive impairment (MCI) due to Alzheimer's disease. It's an antibody that binds to